Medicenna Raises Up to $13M in Public Offering and Equity Deal
Event summary
- Medicenna files prospectus supplement for a public offering of 6M–10M units at $0.50 per unit, targeting $3M–$5M in gross proceeds.
- Sorbie Bornholm LP commits to invest $8M in Medicenna through a combination of equity and an equity swap agreement.
- First closing of the public offering expected on or about May 27, 2026, subject to minimum subscription and regulatory approvals.
- Medicenna’s shares, warrants, and broker warrants are conditionally approved for listing on the TSX.
- Sorbie’s investment includes an equity swap agreement with a notional amount of $8M, tied to Medicenna’s share price performance.
The big picture
Medicenna’s dual fundraising strategy—combining a public offering with a strategic equity investment—reflects the challenges of financing clinical-stage biotech development. The deal highlights the growing role of specialized investors like Sorbie in providing non-dilutive capital to small-cap healthcare companies. The success of this round will depend on market conditions and Medicenna’s ability to meet regulatory and subscription milestones.
What we're watching
- Funding Execution
- Whether Medicenna can secure the minimum $3M in subscriptions to close the offering by May 27, 2026.
- Share Performance
- How Medicenna’s share price will impact the proceeds from the equity swap agreement with Sorbie.
- Regulatory Approvals
- The pace at which Medicenna obtains final TSX approvals for the listing of its securities.
Related topics